PSA testing rates for prostate cancer increased among men after the US Preventive Services Task Force released updated guidance...
An expert considers the role of BRCA1/2 mutations in metastatic prostate cancer.
Judd Moul, MD, discusses the gravity of new data on systemic therapies for men with castration-resistant prostate cancer and...
Data extrapolated from healthy lifestyle scores and polygenic risk scores found that healthy lifestyle changes were associated with a greater reduction in the risk...
Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr...
In order to properly utilize cancer therapies for personalized care, adequate molecular testing must be performed in patients who are eligible for these therapies,...
Mandar Aras, MD, PhD, discussed the management and prevention of cardiotoxicity in patients receiving systemic therapy for breast cancer at the 38th Annual Miami...
Given the current study findings, investigators suggested intratherapy personalization of chemoradiotherapy may possibly facilitate marked de-escalation of radiotherapy...
Researchers specifically suggested that the 86-SNV score could be incorporated into breast cancer risk prediction models for patients carrying a pathogenic variant in BRCA1, BRCA2, and...